Results 81 to 90 of about 9,532 (171)

Pomalidomide is effective for prevention and treatment of experimental skin fibrosis

, 2012
OBJECTIVES: Tissue fibrosis is a major hallmark and a leading cause of death in systemic sclerosis (SSc). Here, we investigated the antifibrotic effects of pomalidomide, an analogue of thalidomide with potent immunomodulatory effects, in preclinical ...
Schett, Georg, Distler, Oliver, Tomcik, Michal, Beyer, Christian, Zerr, Pawel, Distler, Alfiya, Cedzik, Dorota, Shankar, Sai L, Dees, Clara, Schafer, Peter H, Palumbo-Zerr, Katrin, Weingärtner, Simon, Distler, Jörg H W   +12 more
core   +1 more source

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan

Hematology
Background/purpose The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan.Methods This retrospective, chart review-based,
Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang   +7 more
doaj   +1 more source

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

, 2018
IF 3.083International audienceThe combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome.
Rodon, Philippe, Moreau, Philippe, Attal, Michel, Brigitte Pegourie, Caillot, Denis, Richez, Valentine, Claire Mathiot, Garderet, Laurent, Escoffre-Barbe, Martine, Laurent Garderet, Carla Araujo, Pegourie, Brigitte, Fermand, Jean Paul, Bruno Royer, Mathiot, Claire, Royer, Bruno, Michel Attal, Marie Odile Petillon, Brigitte Kolb, Philippe Moreau, Wetterwald, Marc, Margaret Macro, Jean Paul Fermand, Decaux, Olivier, Sabine Brechiniac, Guillemette Fouquet, Cyrille Hulin, Denis Caillot, Marc Wetterwald, Stoppa, Anne-Marie, Petillon, Marie Odile, Benboubker, Lotfi, Araujo, Carla, Facon, Thierry, Bertrand Arnulf, Dib, Mamoun, Brechiniac, Sabine, Karlin, Lionel, Kolb, Brigitte, Roussel, Murielle, Anne-Marie Stoppa, Mamoun Dib, Aurore Perrot, Thierry Facon, Murielle Roussel, Macro, Margaret, Xavier Leleu, Valentine Richez, Philippe Rodon, Hervé Avet-Loiseau, Avet-Loiseau, Hervé, Fouquet, Guillemette, Olivier Decaux, Perrot, Aurore, Leleu, Xavier, Hulin, Cyrille, Lotfi Benboubker, Mourad Tiab, Martine Escoffre-Barbe, Lionel Karlin, Tiab, Mourad, Arnulf, Bertrand   +61 more
core   +1 more source

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

Nature Communications
Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b study (ClinicalTrials.gov., NCT03143985) to determine the primary endpoints of ...
Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J. Ignatz-Hoover, Leland Metheny, Seong Jin Kim, James J. Driscoll   +9 more
doaj   +1 more source

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Frontiers in Oncology
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 and ...
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic   +8 more
doaj   +1 more source

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

, 2017
Key PointsNo new safety signals were observed with daratumumab plus pomalidomide and dexamethasone, except for increased neutropenia. Daratumumab plus pomalidomide and dexamethasone induced rapid, deep, and durable responses in heavily treated patients ...
Nushmia Z. Khokhar, Attaya Suvannasankha, Jonathan L. Kaufman, Kerri Nottage, Suzanne Lentzsch, Tahamtan Ahmadi, Brendan M. Weiss, Ajai Chari, Raymond Comenzo, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Sagar Lonial, Christopher Chiu, Joseph W. Fay, Amrita Krishnan, Jianping Wang   +15 more
core   +1 more source

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

, 2017
Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide.
Russo F., Perlini S., Milani P., Palladini G., Basset M., Foli A., Merlini G.   +6 more
core   +1 more source

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

, 2018
BACKGROUND: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma.
Suzuki, K., Rafferty, B., Raab, M.S., San-Miguel, J., Leleu, X., Jou, Y.-M., Richardson, P.G., Robbins, M., Takezako, N., Dytfeld, D., Moreau, P., LeBlanc, R., Shelat, S.G., Dimopoulos, M.A., McKiver, M.P., Grosicki, S., Hori, M.   +16 more
core   +1 more source

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

eJHaem
Introduction Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. Methods This Phase 2 study evaluated magrolimab (Magro)
Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Usmani, Mei Dong, Lin Gu, Carmen Leung, Parul Doshi, Christine Chen, Ludek Pour   +19 more
doaj   +1 more source

Bumped pomalidomide-based PROTACs

Communications Chemistry
Pomalidomide is an E3 ligase recruiter exploited by PROTACs to degrade target proteins, but its application is hampered by the off-target degradation of other vital endogenous zinc finger (ZF) proteins.
Huijuan Guo
doaj   +1 more source